Enveric Biosciences Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Enveric Biosciences has a total shareholder equity of $5.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.1M and $645.3K respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
Faiz karşılama oranı | n/a |
Nakit | US$3.50m |
Eşitlik | US$5.41m |
Toplam yükümlülükler | US$645.34k |
Toplam varlıklar | US$6.05m |
Son finansal sağlık güncellemeleri
Recent updates
An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% Undervalued
Jul 02Enveric Biosciences to raise $8M in stock offering for corporate use
Jul 25Enveric Biosciences Goes Psychedelic With MagicMed Acquisition
May 31Enveric Biosciences announces $10M registered direct offering
Jan 12Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ENVB's short term assets ($5.5M) exceed its short term liabilities ($645.3K).
Uzun Vadeli Yükümlülükler: ENVB has no long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ENVB is debt free.
Borcun Azaltılması: ENVB currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: ENVB has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: ENVB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.9% each year